Government financing for health and specific national budget lines: the case of vaccines and immunization.

Immunization Vaccines and Biologicals Department (IVB), Expanded Programme on Immunization (EPI), World Health Organization (WHO), Office: M235, 20 Avenue Appia, CH-1211 Geneva 27, Switzerland.
Vaccine (Impact Factor: 3.49). 08/2008; 26(51):6727-34. DOI: 10.1016/j.vaccine.2008.06.090
Source: PubMed

ABSTRACT A long standing question related to immunization financing and sustainability has been whether the existence of a specific line item for vaccines purchasing within the national health budget can contribute significantly to increasing national government financing of vaccines and routine immunizations. Based on immunization financing indicators from 185 countries collected through the joint WHO and UNICEF monitoring system, this paper attempts to answer this policy question. The study will present findings related to the status of countries that have such specific budget lines for purchasing vaccines and the levels of national budgetary allocation to the financing of vaccines and immunizations, particularly in low-income countries. The analysis shows evidence that the existence ofa specific line in the national budget is associated with increased governmental budget allocations for vaccines and routine immunization financing.

  • [Show abstract] [Hide abstract]
    ABSTRACT: This research begins by providing background on the status and literature of childhood immunization in the USA. Vaccine-preventable diseases have been on the rise in Europe and the USA in the last few years. Cases of measles and pertussis have all been increasing at alarming rates. The article begins with a discussion of the use of immunization exemptions across the states and a brief history of US immunization policy. A review of the literature confirms that socioeconomic status and other demographic characteristics can be important predictors of childhood vaccine uptake. Given the seriousness of this public health issue, the primary objective of this research is to analyze the determinants of a child in the USA being fully vaccinated. A range of socioeconomic and demographic characteristics, along with data from the National Immunization Survey, are used to develop an immunization prediction model. Logistic regression is the chosen method in determining whether a preschool-age child in the USA today is likely to be vaccinated based on various demographic and socioeconomic characteristics. Model results reveal a number of significant socioeconomic and demographic characteristics that contribute to the likelihood of a child being immunized. The overall logistic regression model was highly significant at the 5 % level and model parameters are significant. Significant variables in the model include categories of educational attainment, first born child, race and ethnicity, age of mother, and census region. This model does not definitively reveal that later born children are less likely to get fully vaccinated than first born children but does confirm the significance of geography in immunization outcomes. All levels of education were found to be significant along with all census regions. Overall, these models reveal that demographic and socioeconomic characteristics are predictors of childhood immunization and if leveraged appropriately can assist policy makers and public health officials to understand immunization rates and craft policy to improve them.
    Applied Health Economics and Health Policy 02/2015; 13(2). DOI:10.1007/s40258-015-0157-6
  • Source
  • [Show abstract] [Hide abstract]
    ABSTRACT: We evaluated emergency department (ED) provider adherence to guidelines for concurrent HIV-sexually transmitted disease (STD) testing within an expanded HIV testing program and assessed demographic and clinical factors associated with concurrent HIV-STD testing. We examined concurrent HIV-STD testing in a suburban academic ED with a targeted, expanded HIV testing program. Patients aged 18-64 years who were tested for syphilis, gonorrhea, or chlamydia in 2009 were evaluated for concurrent HIV testing. We analyzed demographic and clinical factors associated with concurrent HIV-STD testing using multivariate logistic regression with a robust variance estimator or, where applicable, exact logistic regression. Only 28.3% of patients tested for syphilis, 3.8% tested for gonorrhea, and 3.8% tested for chlamydia were concurrently tested for HIV during an ED visit. Concurrent HIV-syphilis testing was more likely among younger patients aged 25-34 years (adjusted odds ratio [AOR] = 0.36, 95% confidence interval [CI] 0.78, 2.10) and patients with STD-related chief complaints at triage (AOR=11.47, 95% CI 5.49, 25.06). Concurrent HIV-gonorrhea/chlamydia testing was more likely among men (gonorrhea: AOR=3.98, 95% CI 2.25, 7.02; chlamydia: AOR=3.25, 95% CI 1.80, 5.86) and less likely among patients with STD-related chief complaints at triage (gonorrhea: AOR=0.31, 95% CI 0.13, 0.82; chlamydia: AOR=0.21, 95% CI 0.09, 0.50). Concurrent HIV-STD testing in an academic ED remains low. Systematic interventions that remove the decision-making burden of ordering an HIV test from providers may increase HIV testing in this high-risk population of suspected STD patients.
    Public Health Reports 01/2014; 129(Suppl 1):12-20. · 1.64 Impact Factor


Available from